ROC curve of normal cytology <i>vs</i>. ≥AIN 1 and ≥ AIN 2 lesions.

<p>ROC curve of normal cytology <i>vs</i>. ≥AIN 1 and ≥ AIN 2 lesions.</p

Degree of correlation between anal cytology and HR-HPV PCR, with histology

<p>Kappa: Kappa index; p* significance.</p

General description of the patient cohort, and results of the PCR of HPV, cytology and anoscopy.

<p>MSM: males who have sex with males; VL: viral load; HCV: hepatitis C virus infection; HBV: hepatitis B virus infection; SAU: standard alcohol units; ex-IVDA: ex-intravenous drug abuser; SD: standard deviation; STD: sexually transmitted diseases; IQR (inter-quartile range).</p

Results of the PCR of HPV, cytology and anoscopy.

<p>HPV: human papilloma virus; HR-HPV: high-risk human papilloma virus, LR-HPV: low-risk human papilloma virus; LSIL: low-grade squamous intraepithelial lesion; HSIL: high-grade squamous intraepithelial lesion; ASC: atypical squamous cells; AIN: anal intraepithelial neoplasia. IQR (inter-quartile range).</p

Risk factors associated with the appearance of lesions ≥AIN2. Univariate analysis.

<p>MSM-HIV-positive: males who have sex with males HIV-positive, VL: viral load; HCV: hepatitis C virus; HBV: hepatitis B virus; HPV: human papilloma virus; VL: HIV viral load; HR-HPV: high risk human papilloma virus; LR-HPV: low risk human papilloma virus; IQR: inter-quartile range.</p

mtPIrtv in Andalusian 2-2-2016

mtPIrtv in Andalusian 2-2-201

Baseline patients’ characteristics.

<p>Baseline patients’ characteristics.</p

Kaplan-Meier estimations of the efficacy as determined by on-treatment analysis applying different criteria for virological failure.

<p>Kaplan-Meier estimations of the efficacy as determined by on-treatment analysis applying different criteria for virological failure.</p

Percentages of detectable HIV-RNA determinations (red) according to virological behavior during the follow-up for ritonavir-boosted protease inhibitor monotherapy.

<p>Undetectable viremia (green).</p

Efficaccy rates.

<p>A) Efficacy rates according to the ritonavir-boosted protease inhibitor used by intention-to-treat and by on-treatment analyses. B) Virological efficacy rates according to virological failure (VF) defined as >200 copies/mL or C) >50 copies/mL or treatment change due to a single positive viremia, according to the presence or absence of previous VF on a non-boosted protease inhibitor- and/or ritonavir-boosted protease inhibitor-based regimen (PI/rtv). DRV/rtv, darunavir/ritonavir; LPV/rtv, lopinavir/ritonavir.</p